NASDAQ:GTHX
G1 Therapeutics Inc Stock News
$4.53
-0.150 (-3.21%)
At Close: May 17, 2024
2 Biotech Stocks to Watch Under $20
02:37pm, Thursday, 09'th May 2024
Biotech stocks are a tricky bunch, prone to wild moves and technical patterns that are tough to nail down.
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:50pm, Wednesday, 01'st May 2024
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisa
G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript
12:04pm, Wednesday, 01'st May 2024
G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry -
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
08:41am, Wednesday, 01'st May 2024
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.53 per share a year ago.
G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
06:30am, Wednesday, 01'st May 2024
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Eff
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
06:25am, Wednesday, 01'st May 2024
RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world's first transomics drug d
G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024
09:00am, Wednesday, 17'th Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financ
G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
10:30am, Thursday, 04'th Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Baile
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:20pm, Monday, 01'st Apr 2024
RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
05:51pm, Friday, 22'nd Mar 2024
G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effec
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:20pm, Friday, 01'st Mar 2024
RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exerci
G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
02:45pm, Wednesday, 28'th Feb 2024
G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
08:41am, Wednesday, 28'th Feb 2024
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.73 per share a year ago.
G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
06:30am, Wednesday, 28'th Feb 2024
- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - -
G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
08:30am, Tuesday, 27'th Feb 2024
RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey